You are here: Industry Insights > Hengrui

News List

Hengrui's Application for New Class 1.1 Drug Hetrombopag Ethanolamine Tablets was Accepted by CDE PharmaSources/Dopine
June 19, 2020
On June 18, the marketing application of Hengrui's new class 1.1 drug Hetrombopag ethanolamine tablets was accepted by CDE.
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China prnasia
November 22, 2021
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines...
Jiangsu Hengrui's Second Indication Application for Camrelizumab to be Approved for Marketing in China En-CPhI.CN
February 28, 2020
According to NMPA, the second indication of Jiangsu Hengrui's PD-1Camrelizumab to treat liver cancer is close to be approved for martketing soon.
Hengrui's Class 1 New Drug Fluzoparib has been Applied for New Clinical Trials PharmaSources/Caicai
February 03, 2020
Sun Piaoyang’s Leaving Office Will Not Stop Hengrui from Moving Forward
A Review of Progress of Immunotherapy Drugs for Hodgkin’s Lymphoma PharmaSources/Yefenghong
July 03, 2019
The news widespread in the industry that Hengrui has received the pharmaceutical product registration approval for its anti-PD-1 camrelizumab has been confirmed recently. It took 24 days from the beginning of review to the receipt of approval on May 29.
Big Secret Uncovering! Hengrui’s SHR-1603 just Approved for Clinical Trial is Next Anti-CD47 Star in the Tumor Immunotherapy Field! Caicai
August 03, 2018
Hengrui announced at the end of last month that it had received the Drug Clinical Trial Approval issued by the State Drug Administration of China (SDA) and would conduct Phase I clinical trial soon.